Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 10/20 | 0.54 |
| ▸ | CA1 | P00915 | 9/20 | 0.54 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.49 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.49 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.49 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Toluenesulfonamide SCHEMBL8964918 | 0.92 | TDP1 (0.60) | TDP1L3MBTL1TSHRCA2CA1 | |
| P-Toluenesulfonamide SCHEMBL28101678 | 0.86 | CA2 (0.73) | TDP1L3MBTL1TSHRCA2CA1 | |
| SCHEMBL29129907 | 0.81 | CA1 (0.46) | TDP1L3MBTL1TSHRCA2CA1 | |
| P-Toluenesulfonamide SCHEMBL4747609 | 0.80 | ALDH1A1 (0.50) | TSHRCA2CA1CA12CA4 | |
| SCHEMBL11179937 | 0.79 | TDP1 (0.61) | TDP1L3MBTL1ALDH1A1PLAAT3PLAAT5 | |
| SCHEMBL1371070 | 0.79 | KEAP1 (0.61) | TDP1L3MBTL1ALDH1A1PLAAT5PLAAT4 | |
| P-Toluenesulfonamide SCHEMBL28234027 | 0.75 | CA1 (0.66) | L3MBTL1CA2CA1CA12CA4 | |
| SCHEMBL28539623 | 0.74 | L3MBTL1 (0.60) | TDP1L3MBTL1CA12CA9ALDH1A1 | |
| P-Toluenesulfonamide SCHEMBL5691991 | 0.74 | CA2 (0.82) | CA2CA1CA12CA4CA9 | |
| SCHEMBL28161888 | 0.74 | ALDH1A1 (0.54) | CA2CA1CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373997-A1 | IMDQ-PEG-CHOL ADJUVANT AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4225366-A1 | IMDQ-PEG-CHOL ADJUVANT AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4142775-A1 | TREATMENT AND/OR PREVENTION OF A DISEASE OR A SYNDROME RELATED TO A VIRUS INFECTION | Atlas Biotechnology S.A. (CH) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021219896-A1 | TREATMENT AND/OR PREVENTION OF A DISEASE OR A SYNDROME RELATED TO A VIRUS INFECTION | ATLAS BIOTECHNOLOGY S.A. (CH) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021069891-A1 | ANTIVIRAL COMPOUNDS AND METHODS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2021-04-15 | — | — | WO | disclosed |
| WO-2018006014-A1 | COMPOSITIONS AND METHODS FOR PROVIDING A PROGNOSIS FOR INFLUENZA INFECTION | EMERGING VIRAL DIAGNOSTICS (HK) LIMITED (CN) | 2018-01-04 | — | — | WO | disclosed |
| EP-2318045-A1 | MODIFICATION OF ALLERGENS FOR IMMUNOTHERAPY | Hal Allergy Holding B.V. (NL) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010000873-A1 | MODIFICATION OF ALLERGENS FOR IMMUNOTHERAPY | HAL ALLERGY HOLDING B.V. (NL) | 2010-01-07 | — | — | WO | disclosed |
| US-7094391-B1 | Compositions and methods for administering Borrelia burgdorferi antigens | THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-08-22 | — | — | US | disclosed |
| EP-0876156-A4 | COMPOSITIONS AND METHODS FOR ADMINISTERING BORRELIA BURGDORFERI ANTIGENS | UNIV TEXAS (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-1997026006-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING BORRELIA BURGDORFERI ANTIGENS | THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0672127-A4 | USE OF THIOL REDOX PROTEINS FOR REDUCING DISULFIDE BONDS. | UNIV CALIFORNIA (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0689550-A1 | NOVEL ANTIMICROBIAL PEPTIDES FROM BOVINE NEUTROPHILS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-01-03 | — | — | EP | disclosed |
| US-5459235-A | Beta defensin | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-10-17 | — | — | US | disclosed |
| EP-0672127-A1 | USE OF THIOL REDOX PROTEINS FOR REDUCING DISULFIDE BONDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994021672-A1 | NOVEL ANTIMICROBIAL PEPTIDES FROM BOVINE NEUTROPHILS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-09-29 | — | — | WO | disclosed |
| US-5212071-A | Nucleic acids encoding a human C3b/C4b receptor (CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 1993-05-18 | — | — | US | disclosed |
| EP-0411031-A4 | THE HUMAN C3B/C4B RECEPTOR (CR1) | — | 1992-02-05 | — | — | EP | disclosed |
| EP-0411031-A1 | THE HUMAN C3b/C4b RECEPTOR (CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 1991-02-06 | — | — | EP | disclosed |
| WO-1989009220-A1 | THE HUMAN C3b/C4b RECEPTOR (CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 1989-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373997-A1 | IMDQ-PEG-CHOL ADJUVANT AND USES THEREOF | LY96, MYD88, CD14 | TDP1 4836/4885L3MBTL1 3904/4885TSHR 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.